Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% - Time to Sell?

Key Points

• Turn Therapeutics shares fell 6.5% to $9.86 in mid-day trading, with volume below its average. The stock remains above its 50-day and 200-day moving averages but trades at a negative price-to-earnings ratio.
• Analyst sentiment has improved, with recent upgrades ranging from “Hold” to “Strong Buy.” However, the consensus rating is “Moderate Buy” and the average price target of $8.00 is below the current share price.
• The company reported a quarterly loss of $0.03 per share, while analysts expect a full-year loss of $0.09 per share. Several institutional investors initiated positions during the fourth quarter.

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) dropped 6.5% during mid-day trading on Thursday . The company traded as low as $9.80 and last traded at $9.86. 64,512 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 77,022 shares. The stock had previously closed at $10.54.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TTRX. Weiss Ratings raised shares of Turn Therapeutics from a "sell (e)" rating to a "sell (d-)" rating in a report on Monday, July 13th. Wall Street Zen upgraded Turn Therapeutics to a "hold" rating in a research note on Saturday, July 18th. Zacks Research raised Turn Therapeutics to a "hold" rating in a research report on Tuesday, July 21st. Finally, LADENBURG THALM/SH SH upgraded Turn Therapeutics to a "strong-buy" rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.00.

Turn Therapeutics Price Performance

The stock has a market capitalization of $293.71 million and a price-to-earnings ratio of -34.00. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.97. The business's 50 day simple moving average is $7.95 and its 200-day simple moving average is $5.31.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter. On average, research analysts forecast that Turn Therapeutics Inc. will post -0.09 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hodges Capital Management Inc. bought a new stake in Turn Therapeutics during the fourth quarter worth $39,000. LPL Financial LLC bought a new stake in shares of Turn Therapeutics during the fourth quarter worth about $51,000. Tamar Securities LLC acquired a new position in shares of Turn Therapeutics in the fourth quarter valued at approximately $59,000. Composition Wealth LLC acquired a new position in shares of Turn Therapeutics in the fourth quarter valued at approximately $63,000. Finally, Jane Street Group LLC bought a new position in Turn Therapeutics in the 4th quarter valued at approximately $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source